Vanguard Group Inc. Sells 79,767 Shares of Haemonetics Corporation $HAE

Vanguard Group Inc. lessened its position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 1.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,099,621 shares of the medical instruments supplier's stock after selling 79,767 shares during the period. Vanguard Group Inc. owned approximately 10.15% of Haemonetics worth $324,081,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of HAE. Envestnet Asset Management Inc. increased its holdings in Haemonetics by 9.6% during the 4th quarter. Envestnet Asset Management Inc. now owns 48,068 shares of the medical instruments supplier's stock worth $3,753,000 after acquiring an additional 4,217 shares during the period. Raymond James Financial Inc. bought a new stake in Haemonetics during the 4th quarter worth approximately $19,002,000. Marshall Wace LLP increased its holdings in Haemonetics by 25.6% during the 4th quarter. Marshall Wace LLP now owns 279,997 shares of the medical instruments supplier's stock worth $21,862,000 after acquiring an additional 57,116 shares during the period. Dimensional Fund Advisors LP increased its holdings in Haemonetics by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock worth $77,470,000 after acquiring an additional 10,990 shares during the period. Finally, MetLife Investment Management LLC increased its holdings in Haemonetics by 5.9% during the 4th quarter. MetLife Investment Management LLC now owns 57,766 shares of the medical instruments supplier's stock worth $4,510,000 after acquiring an additional 3,241 shares during the period. Institutional investors own 99.67% of the company's stock.

Haemonetics Trading Up 4.3%

HAE traded up $2.2970 during trading on Friday, hitting $56.2770. 1,147,164 shares of the stock traded hands, compared to its average volume of 1,234,426. The firm has a market capitalization of $2.71 billion, a P/E ratio of 17.21, a price-to-earnings-growth ratio of 0.99 and a beta of 0.40. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. The firm has a 50-day moving average of $69.50 and a 200 day moving average of $66.32. Haemonetics Corporation has a 12-month low of $50.68 and a 12-month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business had revenue of $321.39 million during the quarter, compared to analyst estimates of $305.12 million. During the same period in the prior year, the business earned $1.02 EPS. The company's revenue for the quarter was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities research analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $68.00 target price (down previously from $84.00) on shares of Haemonetics in a report on Thursday, August 7th. JMP Securities reissued a "market outperform" rating and issued a $100.00 price target on shares of Haemonetics in a report on Tuesday, May 20th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Citigroup raised shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target on the stock in a report on Wednesday, July 9th. Finally, Mizuho decreased their price target on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Haemonetics currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.18.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.